English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect Dis 2005; 5: 88. 2 Ellis-Grosse EJ, Babinchak T, Dartois N et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. 3 Tanaseanu C, Bergallo C, Teglia O et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. 4 Curcio D. Tigecycline for treating bloodstream infections: a critical analysis of the available evidence. 6 Jenkins I. Linezolid-and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. 7 Schutt AC, Bohm NM. Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. 9 Florescu I, Beuran M, Dimov R et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. 10 Cunha BA. Once-daily tigecycline therapy of multidrug-resistant and non-multidrug-resistant Gram-negative bacteraemias. 12 Anthony K, Fishman N, Linkin D et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. Use of tigecycline for the treatment of prolonged bacteraemia due to a multiresistant VIM-1 and SHV-12 b-lactamase-producing Klebsiella pneumoniae epidemic clone. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-b-lactamase in a Greek university hospital. 18 Rolston K, Raad I, Hachem R et al. Tigecycline use in cancer patients with serious infections. A report on 110 cases from a single institution. Fungicidal activity of anidulafungin in serum from patients does not correlate to its susceptible breakpoint against Candida spp. Sir, Echinocandins, such as anidulafungin, are now considered a primary treatment for patients with suspected candidiasis or candidaemia. 1 Common Candida spp. are highly susceptible to these antifungal agents and .99% of isolates are inhibited by 2 mg/L, the current susceptible breakpoint. 2 In vitro time – kill studies find that echinocandins are fungicidal against Candida spp. at concentrations achieved in serum. 3 A major concern with the results from in vitro studies is the absence of testing in the presence of serum proteins. The echinocandins are highly …